Interferons in dermatology. Present-day standard (Q44264423)

1 December 2017

1 reference

title

Interferons in dermatology. Present-day standard (English)

1 reference

1 December 2017

Stadler R

1

1 reference

1 December 2017

publication date

1 April 1998

1 reference

1 December 2017

1 reference

1 December 2017

volume

16

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

377-398

1 reference

The human interferon alpha-receptor protein confers differential responses to human interferon-beta versus interferon-alpha subtypes in mouse and hamster cell transfectants.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Molecular cloning and expression of the human interferon-gamma receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Isolated limb perfusion for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Cutaneous reactions to recombinant cytokine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Local therapy and adjuvant interferon therapy in genital papilloma virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Modulation of murine and human interferon-gamma receptor expression by their ligands or phorbol ester

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

1 reference

7 January 2021

Biologic therapy of melanoma with cytokines and lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The interferons and their use in condyloma acuminata

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Phase II trial of 13-cis retinoic acid plus interferon-alpha in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

MR imaging of hepatic hemangiomas of infancy and changes seen with interferon alpha-2a treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferons in human papillomavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Intralesional interferon therapy for basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon alpha/beta-induced gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Spindle cell (Kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

lnterferon-α in combination with corticosteroids improves systemic mast cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Use of interferon-alpha in laryngeal papillomatosis: eight years of the Cuban national programme.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Tissue-specific targeting of cytokine unresponsiveness in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Intralesional alfa-2a interferon therapy for basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Cloning and Expression of a Long Form of the β Subunit of the Interferon αβ Receptor That Is Required for Signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Lichen planus and virus C hepatitis: disappearance of the lichen under interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Roferon-A in combination with Tigason in cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of herpes zoster. Recombinant alpha interferon versus acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Combined modality therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cellsin vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Cavernous haemangioma with Kasabach-Merritt syndrome: treatment with alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon-alpha 2b for refractory ocular Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Alpha interferon-induced hair discolouration

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Eosinophilic pustular folliculitis effectively treated with recombinant interferon-gamma: suppression of mRNA expression of interleukin 5 in peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Modulation of human papillomavirus type 16 mRNA in cervical invasive carcinoma patients by interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of basal cell carcinoma with intralesional interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Configuration of the Interferon-α/β Receptor Complex Determines the Context of the Biological Response

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of basal cell carcinoma with intralesional interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Effects of interferon-alpha-2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

MHC antigens in interferon γ (IFNγ) receptor deficient mice: IFNγ-independent up-regulation of MHC class II in renal tubules

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Recombinant interferon gamma therapy for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Effects of intradermal gamma-interferon in cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A novel member of the interferon receptor family complements functionality of the murine interferon gamma receptor in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon-alpha therapy for multiple hemangiomas associated with coarctation of the aorta

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

13-cis retinoic acid and interferon-alpha +/- irradiation in the treatment of squamous-cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The role of CD2 as a regulator of human T-cell cytokine production

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A patient with plaque-stage mycosis fungoides has successfully been treated with long-term administration of IFN-gamma and has been in complete remission for more than 6 years

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon-alpha hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon reduces recurrences of basal cell and squamous cell cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Local interferon therapy for lip carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Virus interference. I. The interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The direct effect of interferon-gamma on human eosinophilic leukemia cell lines: the induction of interleukin-5 mRNA and the presence of an interferon-gamma receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Cutaneous T-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon as an adjuvant treatment for genital condyloma acuminatum

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Cutaneous ulcerations resulting from intramuscular injections of interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Other kinases can substitute for Jak2 in signal transduction by interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Widespread skin-limited Langerhans cell histiocytosis: complete remission with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

More on cutaneous reactions to recombinant cytokine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Long-term effect of interferon alpha treatment in mastocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

13-cis-Retinoic Acid and Interferon -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Granulocyte colony-stimulating factor (rh G-CSF) as an adjunct to interferon alpha therapy of neutropenic patients with hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Structural elements required for receptor recognition of human interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The use of interferon alfa-2a for life-threatening hemangiomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Gamma-interferon in evolving allergic contact dermatitis reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Combined therapy with cisplatin and interferon alpha-2b (INTRON-A) in patients with penile carcinoma. Analysis of 2'5' oligo (A) synthetase and circulating interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Role of Recombinant Alpha-Interferon in the Treatment of Advanced Cutaneous Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A case of deep tufted angioma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The human interferon alpha/beta receptor: characterization and molecular cloning

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Ethanol enhances the IFN-gamma, TGF-alpha and IL-6 secretion in psoriatic co-cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon alfa-2a therapy for airway hemangiomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The role of cytokines in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of Angioblastoma with Recombinant Interferon‐α2

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The role of circulating food antigen-specific lymphocytes in food allergic children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Systemic interferon gamma treatment in severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

[13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva]

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

13-cis-retinoic acid plus interferon-alpha: a phase II clinical study in squamous cell carcinoma of the lung and the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Antiviral activity of autocrine interferon-beta requires the presence of a functional interferon type I receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Effect of recombinant human interferon-alpha/2b on epidermal-growth-factor-, estrogen- and progesterone-receptor expression in primary cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Ultraviolet B-exposed major histocompatibility complex class II positive keratinocytes and antigen-presenting cells demonstrate a differential capacity to activate T cells in the presence of staphylococcal superantigens

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Pyoderma gangrenosum in a patient with cryoglobulinemia and hepatitis C successfully treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of head and neck hemangiomas with recombinant interferon alpha 2B

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferons in dermatology.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Response of deep tufted angioma to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The C-terminus of IFN gamma is sufficient for intracellular function

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of childhood cutaneous T-cell lymphoma with alpha-interferon plus PUVA

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of orbital capillary haemangioma with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Modulation of all-trans-retinoic acid administered on intermittent schedule by alpha-interferon 2a in a patient with AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Telogen effluvium due to recombinant interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Alpha and beta interferons and their receptor and their friends and relations.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Domains of interaction between alpha interferon and its receptor components

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Pulmonary cavernous hemangiomatosis treated with interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

CD7-positive Sézary syndrome with a Th1 cytokine profile

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Cytokine profile of tumor cells in mycosis fungoides: successful treatment with intra-lesional interferon-gamma combined with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

Short-term systemic recombinant interferon-gamma treatment is ineffective in recalcitrant condylomata acuminata

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970020-6

7 January 2021

10.1016/S0733-8635(05)70020-6

Identifiers

DOI

1 reference

1 December 2017

1 reference